Breaking News Instant updates and real-time market news.

DXCM

Dexcom

$67.47

-0.45 (-0.66%)

, ABT

Abbott

$52.15

-0.7 (-1.32%)

08:49
09/28/17
09/28
08:49
09/28/17
08:49

Dexcom price target lowered to $62 from $90 at BMO Capital

BMO Capital analyst JoanneK.Wuensch lowered her price target on Dexcom (DXCM) after Abbott (ABT) received FDA approval for a competing product. The analyst says the approval was unexpected, but she says that Dexcom's product is "materially superior." She thinks that the company's "long-term growth story remains intact," and she keeps an Outperform rating on the shares.

DXCM

Dexcom

$67.47

-0.45 (-0.66%)

ABT

Abbott

$52.15

-0.7 (-1.32%)

  • 18

    Oct

DXCM Dexcom
$67.47

-0.45 (-0.66%)

09/28/17
LEHM
09/28/17
NO CHANGE
Target $60
LEHM
Equal Weight
Barclays up Abbott target, lowers Dexcom target on Libre approval
Barclays analyst Matthew Taylor says FDA approval of Abbott Laboratories' (ABT) FreeStyle Libre Flash Glucose Monitoring System, the first continuous glucose monitoring system that can be used by adults to make treatment decisions without a fingerstick, came a bit earlier than consensus expectations with a significantly better than expected label as it allows for dosing or a replacement claim. While Dexcom's (DXCM) system is more accurate, has alerts, and a strong fan base, Abbott's entry into the U.S. market with this label could be disruptive, Taylor tells investors in a research note. He believes Libre could be both market expanding for glucose monitoring devices and take share from other players, including Dexcom. Its lower price could also pressure price in the market, Taylor contends. The analyst raised his price target for Overweight-rated Abbott to $60 from $57 and lowered his price target for Equal Weight-rated Dexcom to $60 from $76.
09/28/17
ADAM
09/28/17
NO CHANGE
Target $69
ADAM
Buy
Dexcom price target lowered to $69 from $90 at Canaccord
Canaccord analyst Kyle rose lowered his price target on Dexcom (DXCM) to $69 from $90 following the announcement that Abbott (ABT) received FDA PMA approval for its FreeStyle Libre glucose monitoring system. Although the approval was expected, the analyst did not expect the label to include an insulin dosing indication, leading to his price reduction. Rose maintained his Buy rating on Dexcom despite the competitive uncertainty ahead.
09/28/17
WEDB
09/28/17
NO CHANGE
Target $76
WEDB
Outperform
Dexcom price target lowered to $76 from $85 at Wedbush
Wedbush analyst Tao Levy lowered his price target for Dexcom (DXCM) to $76 from $85 due to Abbott (ABT) obtaining FDA approval of its FreeStyle Libre CGM sooner and with a better label than anticipated. Nonetheless, the analyst reiterates an Outperform rating on Dexcom's shares as he believes the market opportunity is large enough to support more than one company and Dexcom's G5 CGM offers users several unique advantages that will continue to attract new users to its system. Further, Levy believes Dexcom could accelerate its own no-calibration CGM regulatory program and potentially obtain FDA approval by the end of 2018.
09/28/17
SPHN
09/28/17
NO CHANGE
Target $70
SPHN
Overweight
Abbott Libre dosing claim a 'black swan event' for Dexcom, says Stephens
While Abbott (ABT) receiving FDA approval of it FreeStyle Libre glucose monitor was "fully expected," the apparent dosing claim for adult patients was a "black swan event," said Stephens analyst Chris Cooley, who cut his price target on Dexcom (DXCM) to $70 from $83 after the unexpected news. He keeps an Overweight rating on Dexcom shares, though, as he sees the CY18 outlook as challenged but thinks the company will be able to ultimately re-accelerate top-line growth given the expected clearance of G6 and user preference for accuracy and functional CGM data.
ABT Abbott
$52.15

-0.7 (-1.32%)

TODAY'S FREE FLY STORIES

MDGL

Madrigal Pharmaceuticals

$47.52

0.51 (1.08%)

08:42
10/19/17
10/19
08:42
10/19/17
08:42
Initiation
Madrigal Pharmaceuticals initiated  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

RMBL

RumbleON

$9.30

0.3 (3.33%)

08:42
10/19/17
10/19
08:42
10/19/17
08:42
Syndicate
RumbleON 2.91M share Secondary priced at $5.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

XPO

XPO Logistics

$64.76

0.12 (0.19%)

08:40
10/19/17
10/19
08:40
10/19/17
08:40
Hot Stocks
Department of Defense boosts XPO contract by $139.5M to $2.32B »

The Department of Defense…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

GEMP

Gemphire Therapeutics

$9.54

-0.08 (-0.83%)

08:40
10/19/17
10/19
08:40
10/19/17
08:40
Initiation
Gemphire Therapeutics initiated  »

Gemphire Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$37.97

0.48 (1.28%)

08:39
10/19/17
10/19
08:39
10/19/17
08:39
Recommendations
eBay analyst commentary  »

eBay progress…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPC

Genuine Parts

$98.04

1.18 (1.22%)

08:39
10/19/17
10/19
08:39
10/19/17
08:39
Hot Stocks
Genuine Parts announces two industrial and automotive acquisitions »

Genuine Parts announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 30

    Oct

BANR

Banner Corp.

$61.29

0.54 (0.89%)

, PUB

People's Utah Bancorp

$32.85

0.2 (0.61%)

08:38
10/19/17
10/19
08:38
10/19/17
08:38
Conference/Events
People's Utah Bancorp to hold a conference call »

Management discusses…

BANR

Banner Corp.

$61.29

0.54 (0.89%)

PUB

People's Utah Bancorp

$32.85

0.2 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 26

    Oct

  • 09

    Nov

MTG

MGIC Investment

$13.54

0.43 (3.28%)

08:37
10/19/17
10/19
08:37
10/19/17
08:37
Recommendations
MGIC Investment analyst commentary  »

MGIC Investment price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$153.00

2.62 (1.74%)

08:37
10/19/17
10/19
08:37
10/19/17
08:37
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Nov

IFMK

iFresh

$12.15

-0.1 (-0.82%)

08:37
10/19/17
10/19
08:37
10/19/17
08:37
Hot Stocks
iFresh announces exclusive agreement with Dragon Seeds »

iFresh announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRBP

Corbus Pharmaceuticals

$7.00

-0.05 (-0.71%)

08:36
10/19/17
10/19
08:36
10/19/17
08:36
Technical Analysis
Technical View: Corbus Pharmaceuticals surges on anabasum Phase 2 results »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$12.33

0.01 (0.08%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Hot Stocks
Celestica appoints Mandeep Chawla as CFO »

Celestica announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPC

Genuine Parts

$98.04

1.18 (1.22%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Hot Stocks
Genuine Parts CEO: Q3 'presented us with both opportunities and challenges' »

Paul Donahue, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 30

    Oct

AXP

American Express

$92.08

0.39 (0.43%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Recommendations
American Express analyst commentary  »

American Express guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 08

    Nov

AXP

American Express

$92.08

0.39 (0.43%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Recommendations
American Express analyst commentary  »

American Express price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 08

    Nov

AGEN

Agenus

$4.71

0.04 (0.86%)

, ADRO

Aduro Biotech

$9.55

-0.1 (-1.04%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Conference/Events
William Blair biotech analyst holds an analyst/industry conference call Aduro Biotech »

Biotech Analyst Phipps,…

AGEN

Agenus

$4.71

0.04 (0.86%)

ADRO

Aduro Biotech

$9.55

-0.1 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 24

    Oct

ARNA

Arena Pharmaceuticals

$27.56

0.71 (2.64%)

08:34
10/19/17
10/19
08:34
10/19/17
08:34
Hot Stocks
Arena Pharmaceuticals reports Phase 2 results of ralinepag in hypertension »

Arena Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VCYT

Veracyte

$9.19

0.29 (3.26%)

08:33
10/19/17
10/19
08:33
10/19/17
08:33
Hot Stocks
Veracyte to present data on Percepta Bronchial Genomic Classifier at CHEST 2017 »

Veracyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPC

Genuine Parts

$98.04

1.18 (1.22%)

08:32
10/19/17
10/19
08:32
10/19/17
08:32
Earnings
Genuine Parts cuts FY17 adjusted EPS view to $4.55-$4.60 from $4.70-$4.75 »

FY17 consensus $4.73.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 30

    Oct

08:32
10/19/17
10/19
08:32
10/19/17
08:32
General news
Jobless Claims data reported »

Week of 10/14 Jobless…

ADBE

Adobe

$153.00

2.62 (1.74%)

08:32
10/19/17
10/19
08:32
10/19/17
08:32
Recommendations
Adobe analyst commentary  »

Adobe growth, margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Nov

08:32
10/19/17
10/19
08:32
10/19/17
08:32
General news
Philadelphia Fed Business Outlook Survey General Conditions Index data reported »

October Philadelphia Fed…

W

Wayfair

$67.13

-0.63 (-0.93%)

08:32
10/19/17
10/19
08:32
10/19/17
08:32
Initiation
Wayfair initiated  »

Wayfair initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

ADBE

Adobe

$153.00

2.62 (1.74%)

08:31
10/19/17
10/19
08:31
10/19/17
08:31
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Nov

UQM

UQM Technologies

$1.13

-0.01 (-0.88%)

, F

Ford

$12.19

-0.08 (-0.65%)

08:31
10/19/17
10/19
08:31
10/19/17
08:31
Hot Stocks
UQM Technologies to collaborate with Lightning Systems for eQVM program by Ford »

UQM Technologies (UQM)…

UQM

UQM Technologies

$1.13

-0.01 (-0.88%)

F

Ford

$12.19

-0.08 (-0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.